LLYLoxo Oncology, Inc.Running, no new patients
A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer
Medullary Thyroid Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 291 (final count)
- Started
- Feb 11, 2020
- Main results expected
- May 22, 2023
- Fully finished
- Nov 2027
- Results posted
- Jun 13, 2024
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression Free Survival (PFS) by Blinded Independent Central Review (BICR)
Measured over: Baseline to Progressive Disease or Death from Any Cause, Whichever Occurs First, Up to 39 Months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT04211337 · record last updated 2026-03-19 · checked 2026-11-09 15:36 UTC